LEVERKUSEN, Germany Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).
The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.
Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.
(Reporting by Frank Siebelt; Writing by Ludwig Burger)
Trending On Reuters
World AIDS Day on Dec. 1
Treatment for HIV patients in South Africa has made huge strides in the last decade but concerns remain as the number of newly infected people each year still outnumbers those who gain access to treatment, with girls and young women most at risk. Full Article